NCT02596958

Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants

Available - Avastin in Addition to Platinum-based Chemotherapy is Indicated for First-lime Treatment of Patients With Locally Advanced, Metastatic or Recurrent Non-small Lung Cancer Other Than Predominantly Squamous Cell Histology

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 996 (actual)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this non-interventional study is the collection and documentation of data on safety and efficacy of intravenous (IV) bevacizumab (Avastin) in addition to platinum-based chemotherapy for first-line treatment in participants with unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology with focus on adenocarcinoma and elderly patients in daily routine.

Conditions

• Non-Squamous Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Bevacizumab	Six 3-weeks cycle of IV bevacizumab will be administered for approximately 7 months.

Timeline

• Start date: 2007-09-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2015-11-04
• Last updated: 2016-04-04
• Results posted: 2016-03-04

Locations

1 site across 1 country: Germany